Login
Navigate Fool.com
Will SNY beat
the market?

Sanofi (ADR)

NYSE: SNY

Community Rating: 4 Stars: Favorite

52.34 0.67 (1.30%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.95
Previous Close $51.67
Daily Range $51.79 - $52.50
52-Week Range $46.95 - $55.94
Market Cap $138.6B
P/E Ratio 28.14
Dividend (Yield) $1.91 (2.5%)
Ex-Dividend Date
Dividend Pay Date
05/07/14
01/01/70
Volume 863,741
Average Daily Volume 1,603,914
Current FY EPS $3.57

How do you think SNY
will perform against the market?

Top SNY Bull/Bear Pitches

 

CraigMiles (< 20)
Submitted October 30, 2011

Undervalued plus ~3% to 4% dividend.<br />The value has been tricky to estimate as the company has so much equity. If I only consider the present value of the ability to generate FCF I get a value of … More

0 Replies Reply Report this Post
 

anton123 (0)
Submitted June 25, 2009

UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir. “We have to be careful not to taint a medicine which he … More

0 Replies Reply Report this Post

News & Commentary

Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape

With four multiple sclerosis therapies already approved, another under FDA review, and one more in mid-stage studies, this biopharmaceutical company is addressing this disease head on.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

New Stock Coverage: Use (Don't Lose) Your Head in Regeneron

Wall Street ratings agencies set the tone for today's stock market.

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

Sanofi Breaks Below 200-Day Moving Average - Notable for SNY

Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?

Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?

From Oakmark’s Market Beaters: Value + Income

The Cost to Treat Cholesterol Plummets, But Will It Last?

Thanks to growing use of generics, spending on cholesterol treatments is falling. However, that may change once PCSK9 drugs from Amgen (AMGN), Regeneron (REGN), and Pfizer (PFE) reach the market.

2 Ways To Invest in This 1 Big Spending Trend

Double digit growth in the largest category for drug spending may support Sanofi (SNY) and Merck (MRK) through 2016.

Got Allergies? FDA to the Rescue

Spring flowers mean spring allergies and big bucks for an industry hoping to crack the allergy code.

See More SNY News...

Sector

Healthcare

Industry

Drugs

Sanofi (ADR) (SNY) Description

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Website: http://www.sanofi.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks